Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

20.08.2021 | comment

The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours

verfasst von: Wolfgang Jungraithmayr, MD PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Excerpt

Evidence for optimal treatment of thymic epithelial tumours (TET) in advanced stages is limited due to the overall rarity of these tumours. To date, the standard treatment for inoperable and advanced diseases is still chemotherapy. However, with the introduction of immune checkpoint inhibitors (ICIs), new opportunities for the treatment of advanced staged thymomas and thymic carcinomas (TC) became available. ICIs have been proven to show good antitumour activity, at the same time displaying a critical immune-mediated toxicity profile. Here, we discuss the current role of ICI therapy using the example of a patient with a type B2/3 thymoma and point out the double-sided effect of ICI treatment in thymomas or thymic carcinomas. …
Vorheriger Artikel Value of autophagy-related gene 5 (ATG5) expression as a prognostic marker in adults with newly diagnosed acute lymphoblastic leukaemia (ALL)
Nächster Artikel Unresectable pleural mesothelioma—hope or still an unmet medical need?
Literatur
1.
Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Cancer Treat Res. 2015;88:154–9.
2.
Bedekovics J, Beke L, Mokanszki A, et al. Programmed death-ligand 1 (PD-L1) expression in Thymic epithelial tumors. Appl Immunohistochem Mol Morphol. 2020;28:1–9.CrossRef
3.
Weissferdt A, Fujimoto J, Kalhor N, et al. Expression of PD‑1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017;30:826–33.CrossRef
4.
Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347–55.CrossRef
5.
Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162–70.CrossRef
6.
Rajan A, Heery CR, Thomas A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269.CrossRef
7.
Shen L, Chen H, Wei Q. Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report. Front Immunol. 2021;12:621858.CrossRef
8.
Konstantina T, Konstantinos R, Anastasios K, et al. Fatal adverse events in two thymoma patients treated with anti-PD‑1 immune check point inhibitor and literature review. Cancer Treat Res. 2019;135:29–32.
9.
Katsuya Y, Horinouchi H, Seto T, et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 2019;113:78–86.CrossRef
10.
Merveilleux du Vignaux C, Dansin E, Mhanna L, et al. Systemic therapy in advanced Thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13:1762–70.CrossRef
11.
Zander T, Aebi S, Rast AC, et al. Response to pembrolizumab in a patient with relapsing Thymoma. J Thorac Oncol. 2016;11:e147–e9.CrossRef
12.
Chen Q, Huang DS, Zhang LW, et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol. 2018;56:667–71.CrossRef
13.
Girard N, Merveilleux du Vignaux C. Systemic treatment for thymic malignancies. Curr Opin Oncol. 2017;29:112–7.CrossRef
Metadaten
Titel
The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours
verfasst von
Wolfgang Jungraithmayr, MD PhD
Publikationsdatum
20.08.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00737-x

Weitere Artikel der Ausgabe 4/2021

ASCO 2021–Gastroesophageal tumor highlights

Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report

  • Open Access
  • case report

Rare lung cancers—2021 update on challenges, advances, and opportunities

  • editorial

Best of ASCO 2021: new data from triple-negative breast cancer

ASCO 2021 highlights head and neck cancer: nasopharyngeal carcinoma

Ovarian cancer—ASCO annual meeting update 2021